Intracellular signal transduction pathways as potential drug targets for ischemia-reperfusion injury in lung transplantation

Lung transplantation is the primary life-saving treatment option for patients with end stage lung disease. However, about 15−20% of donor lung recipients in the post-transplant period develop primary graft dysfunction, a severe form of ischemia/reperfusion (IR)-induced lung injury, which is a major cause of morbidity and mortality in the first year after transplantation.